Parabilis Medicines priced an upsized $670 million IPO, securing what is described as the largest biotech IPO on record for a newly public company. The oncology-focused developer is also raising additional capital via a concurrent private placement, with proceeds earmarked for advancing its lead Wnt/β-catenin pathway inhibitor zolucatetide and earlier-stage programs. The company plans to use IPO proceeds to support development of zolucatetide across multiple solid tumor indications while continuing Phase 1 efforts. The cancer program emphasis reflects a broader push among investors toward well-capitalized oncology platforms as public market windows reopen. Parabilis previously raised through multiple venture rounds and pre-IPO financing, and its leadership includes CEO Mathai Mammen, MD, PhD. The IPO extends the 2026 momentum in large biotech listings and underscores how investors are rewarding late-stage clinical de-risking and clear program roadmaps. For the sector, the record pricing and oversubscription dynamics signal that high-quality oncology companies with scalable funding plans can still command premium valuation even as cash discipline remains tight elsewhere.